EORTC Melanoma Group
|
|
- Prosper Porter
- 6 years ago
- Views:
Transcription
1 EORTC Melanoma Group : Prospective registry of Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden who undergo Completion Lymph Node Dissection (CLND) or Nodal Observation. EORTC protocol 1208-MG (NCT ) Study Coordinator: Alexander van Akkooi Protocol Date of PRC Amendment reference version approval/notification N Classification Outline January 30, September 09, Version 1.0 / September 09, 2013 Copyright EORTC 2013
2 Contact addresses Writing Committee: Study Steering Committee: Study Coordinator: Clinical Research Physician: Project Manager: Data Manager: Statistician: A. van Akkooi, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, The Netherlands EORTC Headquarters Team, Brussels, Belgium. A. van Akkooi, Rotterdam, The Netherlands A. Testori, Milan, Italy A. Eggermont, Paris, France M. Cook, Guildford, UK L. van Kempen, Montreal, Canada S. Suciu, EORTC Headquarters R. Karra, EORTC Headquarters Alexander van Akkooi Phone: a.vanakkooi@erasmusmc.nl Ravi Karra Phone: ravi.karra@eortc.be Gaetan de Schaetzen Phone: gaetan.deschaetzen@eortc.be Simon Vanderschaeghe Phone: simon.vanderschaeghe@eortc.be Stefan Suciu Phone: stefan.suciu@eortc.be Version / 44 September 09, 2013
3
4 Table of contents: Protocol summary 7 1 Background and introduction Disease background information Rationale of the study 11 2 Objectives of the study General objectives End-points Primary endpoint Secondary endpoints 13 3 Patient eligibility criteria 14 4 Trial Design 15 5 Therapeutic regimens, expected toxicity, dose modifications 16 6 Clinical evaluation, laboratory tests and follow-up At enrollment During the study period Summary table 18 7 Criteria of evaluation Definitions of Sentinel Node Positivity Definitions of relapses Definitions of endpoints Methods of assessment of endpoints Evaluation of morbidity Reporting procedures 21 8 Statistical considerations Statistical design Sample size Registration Statistical analysis plan Primary and secondary endpoints Distant Metastasis Free Interval (primary endpoint) Regional Control Rate (secondary endpoint) Relapse Free Interval (secondary endpoint) 22 Version / 44 September 09, 2013
5 Melanoma Specific Survival (secondary endpoint) Overall Survival (secondary endpoint) Analysis populations Statistical methods Efficacy Morbidity Pre-planned sensitivity or exploratory analyses Prognostic factor analyses Data recoding and display Interim analyses End of study 25 9 Data Monitoring Translational research Objectives Translational research projects Translational Research Project 1: Regulation of DNA replication Rationale Objective Material Translational Research Project 2: Ki-67 expression Rationale Objective Material Translational Research Project 3: Circulating Tumor Cells (CTC) Rationale Objective Material Storage, Handling and Transportation Summary of samples collection and routing Laboratory processing Statistical Analysis Data storage and technical appendices General principles for human biological material (HBM) collection Investigator authorization procedure 30 Version / 44 September 09, 2013
6 12 Patient registration procedure Forms and procedures for collecting data Case report forms and schedule for completion Data flow Quality assurance Control of data consistency Audits External review of histology Ethical considerations Patient protection Subject identification Informed consent Administrative responsibilities The study coordinator The EORTC Headquarters The EORTC group Trial sponsorship Trial insurance Publication policy 38 Table of appendices: Appendix A: References 39 Appendix B: Abbreviations 42 Appendix C: Sentinel Node Surgical and Pathological Procedure 44 Version / 44 September 09, 2013
7 Protocol summary Title of the Study Objective(s) Methodology : Prospective registry of Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden who undergo Completion Lymph Node Dissection (CLND) or Nodal Observation With this prospective registry we aim to evaluate the outcome of patients with a T2-T3 primary melanoma and minimal SN tumor burden, treated by CLND or nodal observation: The main objective is to determine if T2-T3 melanoma patients with minimal SN tumor burden and managed by nodal observation have a 5- year DMFI comparable to similar patients (T2-T3 melanoma patients with minimal SN tumor burden) treated by CLND based on historical data from the literature. We will compare this with SN-negative patients, based on historical data as well. We will also determine the actual proportion of patients and their characteristics, who opt to undergo a CLND compared to those, who opt to undergo nodal observation. This is a prospective registry of all melanoma patients with minimal SN tumor burden attending the participating sites, aiming to evaluate whether management of these patients with serial nodal observation only provides an equal outcome than immediate CLND. Since the focus of this study is represented by patients with minimal SN burden and melanoma of intermediate Breslow thickness, the primary aim population will be composed of T2-T3 (Breslow thickness mm) patients with minimal SN tumor burden. However, T1 and T4 patients with minimal SN tumor burden will be allowed to enter the registry for descriptive analyses. This is not a randomized trial. At each site melanoma patients with minimal SN tumor burden will be managed with CLND or serial nodal observation only according to patient decision, and will be offered the possibility to be included in the registry. Participating patients will be registered after signing the informed consent form and after eligibility criteria have been assessed. Data and blood samples for TR will be collected. Accrual will last approximately 5 years. Patients will be followed up for 10 years. Version / 44 September 09, 2013
8 Number of patients Number planed (Statistical design) Number analyzed Diagnosis and main criteria for inclusion The determination of the sample size was based on results from a more recent evaluation, where patients with melanoma of intermediate Breslow thickness, namely T2-T3 (Breslow thickness mm) (N=110), and minimal SN burden had a 5- and 10-year Melanoma Specific Survival rate of 87% and 80%. As generally, the majority of patients who have distant metastasis die within 1-2 years, one may estimate that the 5-year Distant Metastasis Free Interval (DMFI) rate of this group of patients is probably close to 87%. So, for a comparable group of patients, who would not undertake a CLND, an observed loss in the 5-year DMFI rate of approximately 3% would be considered as acceptable; a higher observed loss of the DMFI rate, compatible with a true 5-yr DMFI rate of 80 % or lower would be considered to be inacceptable. It is expected that 243 patients with an T2-T3 primary tumor and minimal SN tumor burden choosing a serial nodal observation will be registered in 5 years. If out of these 243 patients, in 38 (15.7%) patients or less a Distant Metastasis is reported within 5 years from their study enrollment, so 205 (84.3%) patients or more are DM-Free at 5-years, then one may reject the null hypothesis (the loss in 5-year DMFI rate is >= 7 %, i.e. 5-year DMFI rate is <= 80%) in favor of the alternative (5-year DMFI rate is 87%) with a statistical power of 90% (1-sided alpha=0.05 and beta=0.10, A'Hern design). As a drop-out of 7% is expected, the total number of T2-T3 patients to be registered will be increased to 260 patients. T1 and T4 patients will be excluded from the primary aim population, but allowed to enter the registry for descriptive analyses. Histological evidence of primary cutaneous melanoma Metastases solely confined within the SN: in the sub-capsular space (with no parenchymal infiltration) and with a maximum diameter of the largest metastasis not greater than 0.4 mm or regardless of the site, any sub-micrometastasis with a maximum diameter not greater than 0.1 mm If there is more than 1 metastatic SN, the patient will be still eligible provided that all involved SN have minimal tumor burden, regardless of the amount of positive SNs and the basin of interest Absence of clinically apparent metastatic disease at the time of or before undergoing a SN procedure No previous SN procedure for locally recurrent melanoma or uncertain malignant disease, such as atypical Spitz tumor/naevi Age 18 years No history of a previous melanoma (preceding the melanoma which prompted the SN biopsy) No history of any other malignancy within the past 5 years, except for Version / 44 September 09, 2013
9 Treatment Test product, dose and mode of administration Duration of treatment Reference therapy, dose and mode of administration Criteria for evaluation Efficacy non-melanoma skin cancer (Basal Cell Carcinomas or Squamous Cell Carcinomas) and in situ cervical cancer Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations NA NA NA Important note: All eligibility criteria must be adhered to, in case of deviation discussion with Headquarters and study coordinator is mandatory. Primary endpoint Distant Metastasis Free Interval (DMFI), defined as the time from SN positive biopsy until distant metastasis or death due to melanoma, whichever comes first. Secondary endpoints Regional Control Rate (secondary endpoint): Regional Metastasis Free Interval (RMFI): time from SN positive biopsy (date of surgical procedure) until regional relapse, on the same basin as the SN was previously removed. Regional Control Rate (RCR): rate of lymph node relapse (date of delayed CLND) in the same basin as the SN was previously removed. Regional relapse does not include any local or in-transit recurrences. Relapse Free Interval (RFI), defined as the time from SN positive biopsy until first relapse regional or distant metastasis or death due to melanoma. Melanoma Specific Survival (MSS), defined as the time from SN positive biopsy until death due to melanoma. Overall Survival (OS), defined as the time from SN positive biopsy until death due to any cause. Version / 44 September 09, 2013
10 Safety Statistical methods Translational research Quality of Life PK PD Morbidity: rates of wound infections, lymphedema and neurological damage, based on the clinical judgment of the local physician. All the main analyses of the efficacy endpoints will be performed on the intent-to-treat (ITT) population using the ITT principle The Kaplan-Meier technique will be used to obtain estimates of the survival-type distributions and the standard error of the estimates will be computed using the Greenwood formula. Medians - if reached - will be presented with a 2-sided (1-alpha)% confidence interval based on the non-parametric method All the analyses of the morbidities of interest will be performed on the safety population. Morbidities (frequency and percentage, unless otherwise noted) will be reported by arm. To prospectively collect biological material (whole blood, plasma, serum and tissue) for optional translational research projects to gain insight into tumor biology, especially in this study, which targets a specific population of melanoma patients with minimal SN tumor burden. The objective of the optional translational research studies associated with this prospective registry is to answer the following questions: Are micro-metastases within the minimal tumor burden positive SN capable of proliferation and migration? Are any markers of disease dissemination detectable in peripheral blood? Are there any markers, which can predict disease recurrence or disease outcome? In order to explore these questions, this protocol includes a prospective collection of biological material (whole blood, plasma, serum and tissue) from patients who have consented to take part in this research. NA NA Version / 44 September 09, 2013
11 1 Background and introduction 1.1 Disease background information Over the past two decades, the Sentinel Node (SN) biopsy (SNB) procedure has become a standard staging procedure for stage I/II melanoma patients worldwide. It is widely accepted that the SN status is the most important prognostic factor for disease outcome in AJCC stage I/II melanoma patients (Ref. 1, Ref. 2, Ref. 3, Ref. 4). The therapeutic value of the SN procedure followed by early Completion Lymph Node Dissection (CLND) is still widely debated (Ref. 5, Ref. 6, Ref. 7, Ref. 8, Ref. 9, Ref. 10, Ref. 11, Ref. 12, Ref. 13, Ref. 14, Ref. 15, Ref. 16). If a patient has a positive SN, this patient will usually be offered a completion lymph node dissection to remove all lymph nodes from that same nodal basin. However, only approximately 15-20% of all SN positive patients have further lymph node metastases detected in that basin at this time (Ref. 1, Ref. 4, Ref. 17, Ref. 18, Ref. 19). Therefore approximately 80-85% of SN positive patients may undergo unnecessary surgery. Any possible reduction of unnecessary CLND procedures would have an obvious benefit for those patients. Moreover, it remains unclear if the minority (15-20%) of patients with additional nodal involvement at CLND is the subgroup which has a survival benefit by undergoing an early CLND (Ref. 3, Ref. 15, Ref. 16). Over recent years many research groups have looked at different types of micro-staging of the tumor burden within the SN, as indicator or prognostic factor for additional nodal positivity in the CLND specimen, but also for disease-free (DFS), disease/melanoma specific (DSS/MSS) and overall survival (OS). Starz et al. (Ref. 20, Ref. 21) developed a classification for tumor burden by measuring the distance from the capsule to the most interior margin of the metastasis. This was prognostic for the probability of non-sn metastases. Cochran et al. (Ref. 22) calculated the surface area involved by the metastasis and demonstrated its prognostic significance. Dewar et al. (Ref. 23) developed a classification system based on the location of the metastasis within the SN. Subcapsular metastases were accompanied with no additional spread to other lymph nodes in the same lymph node basin. At the same time many studies have identified only very rough cut-off values for SN tumor burden, such as >2 or <2 mm in maximum diameter of the metastasis (Ref. 19, Ref. 24, Ref. 25, Ref. 26, Ref. 27). This was only useful for prognostic purposes, but not for the clinical decision making process. 1.2 Rationale of the study The principle of SUB-micrometastases has been described earlier in breast cancer (Ref. 28, Ref. 29) as metastases <0.2 mm in maximum diameter. It has been demonstrated in breast cancer patients that minimal tumor burden in the SN can be safely managed without performing a CLND (Ref. 28, Ref. 29). However, the question remains if the same situation exists in melanoma. This is an important reason to conduct the present trial. The principle of SUB-micrometastases was defined by van Akkooi et al. (Ref. 4) in melanoma as <0.1 mm in maximum diameter of the largest lesion, regardless of the site within the SN. Patients with SUBmicrometastases in their SN did not have further involvement of their lymph node basin and had excellent prognosis for long-term survival. These results were validated by an EORTC multicenter retrospective study, conducted in 388 patients from Berlin, Rotterdam and Warsaw (Ref. 30). Similarly, a study from Canada by Govindarajan et al. showed that none of the patients with metastases <0.2 mm had additional non-sn metastases in the CLND specimen (Ref. 31). These results were confirmed by the most recent studies, which have also investigated minimal SN tumor burden (Ref. 32, Ref. 33, Ref. 34). Version / 44 September 09, 2013
12 More recently, a large EORTC retrospective analysis by van der Ploeg et al. in 1080 SN positive patients from 9 centers, demonstrated that patients with metastases <0.1 mm in maximum diameter according to the Rotterdam classification for SN tumor burden had a 5-year 91% MSS, which is virtually identical to SN negative patients (Ref. 35). The CLND positivity rate was 9% in these cases. Rotterdam-Dewar Combined (RDC) classification further isolated excellent prognosis patients; in those with <0.1 mm subcapsular metastases had a 2% CLND positivity rate and a 95% 5-year MSS (Ref. 35). In a more recent evaluation (van der Ploeg & van Akkooi, personal communication), the Breslow thickness was confirmed to be an independent prognostic factor. Indeed, the 5-year MSS rate of those SNpositive patients with T1 (Breslow thickness <1 mm) and minimal SN tumor burden (defined as Rotterdam criteria 0.1 mm, or those with a subcapsular infiltration up to 0.4 mm) who received CLND (N=9) was 100%, whereas the 5- and 10-year MSS rate was 67% and 45% for patients with thick melanoma (T4, Breslow thickness > 4 mm) and minimal SN burden (N=21). Meanwhile, patients with melanoma of intermediate Breslow thickness, namely T2-T3 (Breslow thickness mm) (N=110), and minimal SN burden had a 5- and 10-year MSS rate of 87% and 80%. Based on preliminary data (van der Ploeg & van Akkooi, personal communication), the incidence of patients with T1 and T4 tumors presenting with minimal SN tumor burden is nearly non-existent. T1 tumors have very few metastases at all (<5% SN positive), while T4 tumors usually have advanced SN metastases, infrequent cases of minimal SN tumor burden which develop distant metastases within a very short timeframe exist. In addition, as the Breslow thickness remains of high prognostic importance, MSS rates are very high for T1 patients and low for T4 patients, as compared to MSS rates in T2-T3 patients. Hence, T1 and T4 patients represent two population groups with distinct prognostic and clinical characteristics compared to T2-T3 patients. For this reason, T2-T3 patients will be the focus of this study, as it is currently unknown if this patient population really benefits from immediate CLND or not. Patients with T1 and T4 melanomas will be excluded from the primary aim study population, but allowed to enter the registry for descriptive analyses. All these studies suggest that certain patterns or sizes of metastatic spread are not associated with further metastases in other lymph nodes of the same lymph node basin. At the moment the standard practice in most countries (Europe, U.S.A & Australia), as defined in the national guidelines, is that patients with a positive SN, regardless of amount, pattern or size, undergo completion lymph node dissection. This is a second operation for all these patients, which is accompanied with all the risks of a surgical procedure, but is also associated with significant post-operative morbidity, such as wound infections and chronic limb lymphedema (Ref. 36, Ref. 37, Ref. 38, Ref. 39). Although most countries suggest CLND as standard treatment for a positive SN in melanoma, there are large differences in local application of this guideline. A study by Bilimoria et al. demonstrated that only 50% of SN positive patients undergo a CLND in the U.S.A., regardless of SN tumor burden (Ref. 40). Likewise, the treatment of SN positive patients is quite heterogeneous across Europe (Ref. 41). Both CLND and nodal observation (with or without regional nodal ultrasound) are being performed. Based on the previous studies regarding SN tumor burden, some major melanoma centers have adjusted their protocol/standard of care in these cases with minimal SN tumor burden. Moreover, the MSLT-1 study has not yet been able to identify a survival benefit for SN followed by early CLND compared to nodal observation (Ref. 3, Ref. 15, Ref. 16). Therefore, the choice for nodal observation can be justified. Currently, there is one prospective randomized trial worldwide, the MSLT-2, which randomizes SN positive melanoma patients between CLND and nodal observation, regardless of SN tumor burden (Ref. 42). All these previous SN tumor burden studies in melanoma have been retrospective and the majority of included patients have undergone a CLND. Version / 44 September 09, 2013
13 Obviously, a prospective randomized controlled trial of minimal SN tumor burden melanoma patients randomizing between CLND and nodal observation would be the best possible trial design to address this question. However, this is practically impossible, as it would require a large number of patients to test this hypothesis. Therefore, the second best option would be to analyze a prospective registry of minimal SN tumor burden patients managed without CLND to historical data from the retrospective series, as described above, and to SN negative melanoma patient cohorts. In view of the discrepancy in the management of SN positive melanoma patients and in light of the previous retrospective analyses regarding SN tumor burden, any change from the standard of offering a CLND or nodal observation to minimal tumor burden SN positive patients would require an EORTC prospective trial to support this new standard of care and therefore this EORTC prospective registry will be the first to address this question, specifically in targeting minimal SN tumor burden melanoma patients. 2 Objectives of the study 2.1 General objectives With this prospective registry we aim to evaluate the outcome of patients with a T2-T3 primary melanoma and minimal SN tumor burden, treated by CLND or nodal observation: The main objective is to determine if T2-T3 melanoma patients with minimal SN tumor burden and managed by nodal observation have a 5-year DMFI comparable to similar patients (T2-T3 melanoma patients with minimal SN tumor burden) treated by CLND based on historical data from the literature. We will compare this with SN-negative patients, based on historical data as well. We will also determine the actual proportion of patients and their characteristics, who opt to undergo a CLND compared to those, who opt to undergo nodal observation. Answering these questions will be crucial to establish an accepted standard of care (CLND or not) for melanoma patients with minimal SN tumor burden. 2.2 End-points Primary endpoint Distant Metastasis Free Interval (DMFI): time from SN positive biopsy (date of surgical procedure) until distant metastasis or death due to melanoma, whichever comes first Secondary endpoints Regional Control Rate (RCR) is the resultant of two sub-endpoints: Regional Metastasis Free Interval (RMFI), defined as the time from SN positive biopsy (date of surgical procedure) until regional relapse in the same basin as the one from which the SN was previously removed. Regional Control Rate (RCR), defined as the rate of lymph node relapse (date of delayed CLND) in the same basin as the one from which the SN was previously removed. Regional relapse does not include any local or in-transit recurrences. Relapse Free Interval (RFI): time from SN positive biopsy (date of surgical procedure) until first relapse regional or distant metastasis or death due to melanoma. Version / 44 September 09, 2013
14 Melanoma Specific Survival (MSS): time from SN positive biopsy (date of surgical procedure) until death due to melanoma. Overall Survival (OS): time from SN positive biopsy (date of surgical procedure) until death due to any cause. Morbidity: rates of wound infections, lymphedema and neurological damage, based on the clinical judgment of the local physician. 3 Patient eligibility criteria Histological evidence of primary cutaneous melanoma Metastases solely confined within the SN: in the sub-capsular space (with no parenchymal infiltration) and with a maximum diameter of the largest metastasis not greater than 0.4 mm or regardless of the site, any sub-micrometastasis with a maximum diameter not greater than 0.1 mm If there is more than 1 metastatic SN, the patient will be still eligible provided that all involved SN have minimal tumor burden, regardless of the amount of positive SNs and the basin of interest Absence of clinically apparent metastatic disease at the time of or before undergoing a SN procedure No previous SN procedure for locally recurrent melanoma or uncertain malignant disease, such as atypical Spitz tumor/naevi Age 18 years No history of a previous melanoma (preceding the melanoma which prompted the SN biopsy) No history of any other malignancy within the past 5 years, except for non-melanoma skin cancer (Basal Cell Carcinomas or Squamous Cell Carcinomas) and in situ cervical cancer Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations. Important note: All eligibility criteria must be adhered to, in case of deviation discussion with Headquarters and study coordinator is mandatory. Version / 44 September 09, 2013
15 4 Trial Design This is a prospective registry of all melanoma patients with minimal SN tumor burden attending the participating sites, aiming to evaluate whether management of these patients with serial nodal observation only provides an equal outcome than immediate CLND. Since the focus of this study is represented by patients with minimal SN burden and melanoma of intermediate Breslow thickness, the primary aim population will be composed of T2-T3 (Breslow thickness mm) patients with minimal SN tumor burden. However, T1 and T4 patients with minimal SN tumor burden will be allowed to enter the registry for descriptive analyses. This is not a randomized trial (Figure 1). At each site melanoma patients with minimal SN tumor burden will be managed with CLND or serial nodal observation only according to patient decision, and will be offered the possibility to be included in the registry. Participating patients will be registered after signing the informed consent form and after eligibility criteria have been assessed. Data and blood samples for TR will be collected. Accrual will last approximately 5 years. Patients will be followed up for 10 years after registration. Version / 44 September 09, 2013
16 Figure 1. Flow chart showing the study design. SN, sentinel node; CLND, completion lymph node dissection; TR, translational research 5 Therapeutic regimens, expected toxicity, dose modifications Not applicable. Version / 44 September 09, 2013
17 6 Clinical evaluation, laboratory tests and follow-up 6.1 At enrollment A screening log needs to be completed by the investigator to assess potential selection bias. Availability of all required material for the Pathology Review committee within 3 months after entry into the registry. Please refer to Pathology Guidelines for further elaborated information. Medical history and physical examination. Morbidity: rates of wound infections, lymphedema and neurological damage, based on the clinical judgment of the local physician. Minimal staging assessment (chest X-ray and Ultrasound of the liver). Ultrasound of lymph nodes is not requested but result data will be collected for centers performing it routinely. Tissue from SN for Central Pathology review and TR purposes. For optional TR purposes, 3 x 5 ml of whole blood, 1 x 10 ml of serum and 1 x 10 ml tube of plasma (total of 35 ml). Whole blood should be collected in EDTA tubes and stored at -80 degrees Celsius. Serum should be collected in 10 ml tubes to be divided in aliquots of 1 ml and stored at -80 degrees Celsius. Plasma should be collected in heparin tubes, to be divided in 10 x 1 ml aliquots and stored at - 80 degrees Celsius. 6.2 During the study period Recent medical history and physical examination 4-monthly for years 1-2, 6-monthly for years 3-5, once a year for years Ultrasound of lymph nodes 4-monthly for years 1-2, 6-monthly for years 3-5, once a year for years Ultrasound of lymph nodes is not requested but result data will be collected for centers performing it routinely. Chest X-ray once a year for 10 years. Ultrasound of the liver, if clinically indicated. CT-thorax/abdomen, CT/MRI brain, PET-scan if clinically indicated Morbidity: rates of wound infections, lymphedema and neurological damage, based on the clinical judgment of the local physician. For optional TR purposes, 1 x 10 ml of serum and 1 x 10 ml of plasma (total 2 x 10 ml) once a year for 5 years. Further anti-tumor therapy. Survival status. Version / 44 September 09, 2013
18 6.3 Summary table Assessment Screening Log Enrollment X Years 1-2 Years 3-5 Years 6-10 Month Month Once a year History & Physical X X X X X X X X X X X X X X Morbidity X X X X X X X X X X X X X X Chest X-ray X X X X X X X Ultrasound Liver X * * * * * * * * * * * * * Ultrasound of Lymph Nodes CT-thorax/ abdomen, CT/MRI brain, PET-scan Tissue for Pathology Review & optional TR Whole blood for optional TR studies Serum for optional TR studies Plasma for optional TR studies Further anti-tumor therapy C C C C C C C C C C C C C C X X * * * * * * * * * * * * * X X X X X X X X X X X X X X X X X X X X X X X X X Survival status X X X X X X X X X X X X X * If clinically indicated C Only for Centers performing regular lymph node ultrasound examinations All centers must make the primary lesion available in the form of the block and send the original diagnostic slides of the primary melanoma along with all slides stained and unstained from all positive SNs. Additional stained slides from any negative sentinel node(s) removed at the same procedure may be requested for analysis by the Pathology Review committee later. Version / 44 September 09, 2013
19 7 Criteria of evaluation 7.1 Definitions of Sentinel Node Positivity Please refer to Appendix C for the sentinel node surgical and pathological procedure. 7.2 Definitions of relapses Relapse: Appearance of one or more new melanoma lesions: local, regional or distant. Local cutaneous relapse: Local relapse/recurrence is a lesion clearly occurring in continuity within the excision scar of the primary melanoma. Regional lymphatic and nodal relapses: The neoplastic nature of the regional relapses should be attempted to be confirmed by histology/cytology. In Transit Metastases: In transit metastasis represents the clinical manifestation of small tumor emboli trapped within the dermal and subdermal lymphatics between the site of the primary tumor and the regional lymph node drainage basin(s). In extremities in transit metastases can also occur distal to the site of the primary lesion as a result of reversed lymphatic flow. In transit metastases occur in 10% to 15% in patients with stage III disease. Although previous staging systems distinguished between the small satellitosis (within 2 cm of the primary tumor) and in transit metastases (more than 2 cm from the primary tumor), pathophysiologically these two events represent different points on a continuum of the same biologic process. When present, in transit metastases are usually multiple, evolve over time, and, as previously stated, are often the harbinger of subsequent systemic disease (AJCC 2002). Microscopic satellites are defined as any discontinuous nest of metastatic cells more than 0.05 mm in diameter that are clearly separated by normal dermis from the main invasive component of melanoma by a distance of at least 0.3 mm. As per AJCC 2010, satellites and intransit metastases are classified together. Regional Nodal Relapses: Regional nodal failure in a previously dissected basin is usually found at the periphery of the prior surgical procedure. Distant metastases: Melanoma is well known for its ability to metastasize to virtually any organ or tissue. The most common initial sites of distant metastases are the non visceral, such as the skin, subcutaneous tissue, and lymph nodes, which are relapse sites for 42% to 59% of patients in various studies. Visceral locations are the lung, brain, liver, gastrointestinal tract, and bone which are the initial sites of relapse in approximately 25% of all melanoma patients who experienced relapse. Note: Cutaneous relapses occurring beyond the periphery of the previous surgical bed of a lymph nodal dissection scar (i.e. over 2 cm) are considered distant metastases. Node relapses occurring beyond the anatomical compartment of the dissected basins are considered distant metastases. Version / 44 September 09, 2013
20 Node relapses in nodal basins situated in a different anatomical compartment or beyond the previously dissected basin or in two nodal basins (even if contiguous; i.e. 2 pelvic nodal basins, 2 mediastinal nodal basins) are considered distant metastases unless the primary was located within 2 cm from the midline and the nodes are in the same district as the initial nodal involvement. 7.3 Definitions of endpoints Distant Metastasis Free Interval (DMFI) has been defined as the time from SN positive biopsy (date of surgical procedure) until distant metastasis or death due to melanoma, whichever comes first. In case no events occurred, patients will be censored at the last follow-up date. Regional Control Rate (RCR) has been defined as the result of two sub-endpoints: Regional Metastasis Free Interval (RMFI), defined as the time from SN positive biopsy (date of surgical procedure) until regional relapse in the same basin as the one from which the SN was previously removed. Regional Control Rate (RCR), defined as the rate of lymph node relapse (date of delayed CLND) in the same basin as the one from which the SN was previously removed. Regional relapse does not include any local or in-transit recurrences. Relapse Free Interval (RFI) has been defined as the time from SN positive biopsy (date of surgical procedure) until first relapse regional or distant metastasis or death due to melanoma Melanoma Specific Survival (MSS) has been defined as the time from SN positive biopsy (date of surgical procedure) until death due to melanoma Overall Survival (OS) has been defined as the time from SN positive biopsy (date of surgical procedure) until death due to any cause Morbidity has been defined as the rates of wound infections, lymphedema and neurological damage, based on the clinical judgment of the local physician. 7.4 Methods of assessment of endpoints The following methodologies are recommended to assess endpoints Lymph Node Recurrence: cytology or histology. Lung: X-thorax or CT-thorax. Liver: Ultrasound, CT or MRI of the liver. Central Nervous System: brain CT-scan or MRI. (Sub)Cutaneous Recurrence: cytology or histology. Other Organs: CT-scan or MRI-scan or PET-scan; contrast GI series or ultrasound, or cytology or histology. Time points are specified in the table at chapter 6.3. Version / 44 September 09, 2013
21 7.5 Evaluation of morbidity The following morbidities are of interest for this study and will be assessed as present or absent by the local physician: wound infection rates lymphedema rates neurological damage 7.6 Reporting procedures Any confirmed morbidity, distant metastases, regional lymph node relapses, deaths due to melanoma should be reported immediately. Investigators will receive routine requests to enter follow-up data (also for those patients without events) 4-monthly for years 1-2, 6-monthly for years 3-5, once a year for years Statistical considerations 8.1 Statistical design Sample size The primary objective of this study is to determine whether melanoma patients with a T2-T3 primary tumor and minimal SN tumor burden managed only by serial nodal observation have a 5-year Distant Metastasis Free Interval (DMFI) comparable to melanoma patients with minimal SN tumor burden who had CLND and to melanoma patients with a negative SN biopsy, both based on historical data from the literature. The determination of the sample was based on results from a more recent evaluation (van der Ploeg & van Akkooi, personal communication), where patients with melanoma of intermediate Breslow thickness, namely T2-T3 (Breslow thickness mm) (N=110), and minimal SN burden had a 5- and 10-year MSS rate of 87% and 80%. As generally, the majority of patients who have distant metastasis die within 1-2 years, one may estimate that the 5-year DMFI rate of this group of patients is probably close to 87%. So, for a comparable group of patients, who would not undertake a CLND, an observed loss in the 5-year DMFI rate of approximately 3% would be considered as acceptable; a higher observed loss of the DMFI rate, compatible with a true 5-yr DMFI rate of 80 % or lower would be considered to be inacceptable. It is expected that 243 patients with a T2-T3 primary tumor and minimal SN tumor burden choosing a serial nodal observation will be registered in 5 years. If out of these 243 patients, in 38 (15.7%) patients or less a Distant Metastasis is reported within 5 years from their study enrollment, so 205 (84.3%) patients or more are DM-Free at 5-years, then one may reject the null hypothesis (the loss in 5-year DMFI rate is >= 7 %, i.e. 5-year DMFI rate is <= 80%) in favor of the alternative (5-year DMFI rate is 87%) with a statistical power of 90% (1-sided alpha=0.05 and beta=0.10, A'Hern design). As a drop-out of 7% is expected, the total number of T2-T3 patients to be registered will be increased to 260 patients. Patients with T1 or T4 primary tumors will be excluded from the primary aim population, but allowed to enter the registry for descriptive analyses. Version / 44 September 09, 2013
22 8.1.2 Registration Patients will be centrally registered (for practical details, see chapter on registration procedure). 8.2 Statistical analysis plan Primary and secondary endpoints Distant Metastasis Free Interval (primary endpoint) Distant Metastasis Free Interval (DMFI) is defined as the time from SN positive biopsy until distant metastasis or death due to melanoma, whichever comes first. A DMFI event observed up to 4 months after 5 years from SN positive biopsy, will be considered as DMFI events just before 5 years (e.g. at 4.9 yrs). The follow-up of patients without a DMFI-event will be censored at the time of last disease evaluation or at time of death due to other cause than melanoma Regional Control Rate (secondary endpoint) Regional Metastasis Free Interval (RMFI), defined as the time from SN positive biopsy until regional relapse, in the same basin as the SN was previously removed. The follow-up of patients without a RMFIevent will be censored at the time of last disease evaluation or at time of death. Regional Control Rate (RCR) is defined as the rate of lymph node relapse (date of CLND) in the same basin as the SN was previously removed Relapse Free Interval (secondary endpoint) Relapse Free Interval (RFI) is defined as the time from SN positive biopsy until first relapse regional or distant metastasis or death due to melanoma. The follow-up of patients without a RFI-event will be censored at the time of last disease evaluation or at time of death due to other cause than melanoma Melanoma Specific Survival (secondary endpoint) Melanoma Specific Survival (MSS) is defined as the time from SN positive biopsy until death due to melanoma. The follow-up of patients still alive will be censored at the time of last follow-up contact or at time of death due to other cause than melanoma Overall Survival (secondary endpoint) The overall survival (OS) is defined as the time from SN positive biopsy until death due to any cause. The follow-up of patients still alive will be censored at the time of last follow-up contact Analysis populations Intention-to-treat population (ITT): All patients registered in the study Per protocol population: All eligible patients registered in the study Safety population: All patients who have started their chosen treatment (observation or CLND) A patient will be considered to be eligible if he/she did not have any deviation from the patient entry criteria listed in chapter 3 of the protocol. Potential eligibility problems will be assessed by the Clinical Research Physician at time of medical review. Version / 44 September 09, 2013
23 These definitions will be used for the 2 patient populations: those with T2-T3 primary tumors (primary aim study population), and those with T1 or T4 primary melanomas Statistical methods Efficacy All the main analyses of the efficacy endpoints will be performed on the intent-to-treat (ITT) population using the ITT principle: patients will be considered in the arm group they entered at registration, regardless cause of going off-protocol, possible start of treatment before the 1st relapse, etc. In order to have a conservative approach for the 5-yr DMFI rate, we will consider a 4-month time window, so all distant metastases which were observed up to 4 months after 5 years from SN positive biopsy, will be considered as DMFI events just before 5 years (e.g. at 4.9 yrs). The Kaplan-Meier technique will be used to obtain estimates of the survival-type distributions and the standard error of the estimates will be computed using the Greenwood formula. Medians - if reached - will be presented with a 2-sided (1-alpha)% confidence interval based on the nonparametric method (Ref. 30). Patients with T1 or T4 primary tumors, as well as patients that chose CLND at study entry, will be considered separately, using descriptive analyses only, i.e. no inferential analyses will be done for this subpopulation vs the primary aim study population (patients with T2-T3 primary tumor, who did not undergo initial CLND) Morbidity All the analyses of the morbidities (see below) will be performed on the safety population, by chosen arm, in the overall population and in patients with T2-T3 primary tumor only. The safety analyses will be presented at baseline, during the study period as defined below: The baseline period will include all information recorded up to the registration date The study period will start on the first day after the registration and will end when the patient relapses or start further anti-tumor therapy (except local surgery). The following analyses of morbidities (frequency and percentage, unless otherwise noted) will be reported by each arm: wound infection rates (%) lymphedema rates (%) neurological damage (%) Pre-planned sensitivity or exploratory analyses For all endpoints sensitivity analyses will be performed: using the per protocol population In addition, in order to avoid the possible impact of CLND on the study endpoints (efficacy, morbidity) in patients who initially chose not to have CLND performed, the follow-up of patients in the observation arm who received CLND without a proof of relapse, will be censored at the date of CLND. Version / 44 September 09, 2013
24 8.2.5 Prognostic factor analyses Regarding each endpoint, for univariate analysis, a Cox proportional hazards model will be fitted including each of the potential prognostic factors mentioned in the literature: Minimal Tumor Burden (<= 0.1 mm any location vs <=0.2 mm subcapsular vs <=0.3 mm subcapsular vs <=0.4 mm subcapsular) Breslow thickness of the primary (<= 1.0 mm vs mm vs mm vs. > 4.0 mm) Ulceration (yes vs no vs unknown) Site of the primary (central (head, neck or trunk) vs. extremities) Sex (Male vs. Female) Age (<65 vs vs 70 years) Adjuvant treatment is foreseen to start after SNB (no vs IFN vs other) This list is not exhaustive: other variables might also be assessed based on new information that may become available during the course of the study. In order to avoid a possible treatment influence on the prognostic importance of such factors, only patients registered in the serial nodal observation arm will be included. Due to this restriction (implying a loss in the statistical power in detection of prognostic factors), a 2-sided relaxed alpha level (for instance, 20%) will be considered in univariate analyses Data recoding and display Frequency tables will be tabulated (by treatment group or otherwise) for all categorical variables by the levels of the variables as they appear on the CRF (with %). Categories with a text field specification will be tabulated as categories and then supplemented by a listing with the following information for the patients fulfilling the condition for the specification (SeqID, institution, treatment group, value of the item and text field contents). Dates relating to events prior to entry will be presented as the delay in days (or weeks, months, or years) between the past event and the date of entry (date of registration date of past event + 1) and presented using the median and range. Other delays are presented as continuous variables using the median and range. Continuous variables for which a coding system exists will be recoded into categories. Other continuous variables (for example age, ) are presented using the median and range (minimum, maximum). If appropriate, continuous data may also be presented in categories (for example, age may also be grouped in decades). 8.3 Interim analyses No interim analysis is foreseen for any of the endpoints defined in Version / 44 September 09, 2013
25 8.4 End of study End of study occurs when all of the following criteria have been satisfied: 1. Thirty days after all patients have stopped their follow-up up to 10 years from registration as per protocol 2. The trial is mature for the analysis of the primary endpoint as defined in the protocol 3. The database has been fully cleaned and frozen for this analysis 9 Data Monitoring Safety data are reviewed within the EORTC Headquarters on a regular basis as part of the Medical Review process. Problems which are identified will be discussed with the Study Coordinators who will take appropriate measures. Safety information will also be included in trial status reports which serve as a basis of discussion during EORTC Group meetings. These reports will be made available to investigators participating in the study. The EORTC Independent Data Monitoring Committee (IDMC) will review all safety problems identified by the EORTC Headquarters for which an advice is sought. Experts on the IDMC performing this review will be selected to have the relevant early trials/drug development expertise and will provide a review process independent of that of the Medical Review. In principle, no access to outcome data is necessary for safety reviews. However, the IDMC may also advise if they think a full review of all study data and endpoints is needed. 10 Translational research 10.1 Objectives The basic rationale to conduct Translational Research (TR) within a prospective registry is to gain insight into tumor biology, especially in this study, which targets a specific population of melanoma patients with minimal SN tumor burden. The objective of the optional translational research studies associated with this prospective registry is to answer the following questions: Are micro-metastases within the minimal tumor burden positive SN capable of proliferation and migration? Are any markers of disease dissemination detectable in peripheral blood? Are there any markers of prognostic importance regarding the outcome (regional relapse rate, RFI, DMFI, MSS)? In order to explore these questions, this protocol includes a prospective collection of biological material (whole blood, plasma, serum and tissue) from patients who have consented to take part in this research. Version / 44 September 09, 2013
26 10.2 Translational research projects Three optional TR projects, specifically designed at the onset of the study, are reported below. However, the TR to be performed within this prospective registry will not be necessarily restricted to these three correlative studies, as other projects might be defined in due course Translational Research Project 1: Regulation of DNA replication Rationale The Mini-Chromosome Maintenance (MCM) proteins 4 and 6 are two of 7 DNA helicases that form a multimeric protein complex that unwinds DNA during its replication. Their expression in primary tumors correlates with poor DMFS (Ref. 43). To gain a better understanding of the potential malignant power of minimal tumor burden SN lesions, immunohistochemistry of these lesions for MCM4 and MCM6 could teach us if they are truly active lesions or dormant lesions, which are only present as antigen presenters to the immune system for a host response against the cancer. PR70 is a regulatory subunit of the protein phosphatase 2A complex, which antagonizes CDK2/cyclinA mediated phosphorylation of cdc6. Cdc6 phosphorylation is a critical step in the initiation of DNA replication. PR70 is a novel tumor suppressor gene in melanoma and a critical regulator of initiation of DNA replication (van Kempen et al., manuscript in preparation) Objective To determine replication/proliferation capacity of tumor cells in minimum SN tumor burden lesions, the level of expression of MCM 4, MCM6 and PR70 will be determined and their prognostic importance regarding the outcome (regional relapse rate, RFI, DMFI, MSS) will be assessed Material The expression of MCM 4, MCM6 and PR70 will be measured by means of immunohistochemistry of unstained sections of the SN blocks Translational Research Project 2: Ki-67 expression Rationale Ki-67 is a proliferation marker of tumor cells. Since the malignant power of minimal SN tumor burden lesions is unclear, it is of interest to analyze the potential migration capacity of these highly proliferative tumor cells. The question to be answered is: can these cells migrate into the circulation and nest elsewhere in the body, thereby influencing the patient s outcome or are they merely dormant within the SN as antigen presenters for the host s immune response Objective To explore the biological significance of minimal SN tumor burden metastases on patient outcome and their potential role / behavior. The level of expression of Ki-67 and of new biomarkers (BRAF, CD133, Nestin, Integrin, JARID, S1000, Vimentin amongst others) will be determined and their prognostic value regarding the outcome (regional relapse rate, RFI, DMFI, MSS) will be assessed. Version / 44 September 09, 2013
Rebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationSentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC
Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationMorphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.
More informationYou Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018
You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:
More informationSentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins
Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in
More informationMichael T. Tetzlaff MD, PhD
American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary
More informationINTRODUCTION TO CANCER STAGING
INTRODUCTION TO CANCER STAGING Patravoot Vatanasapt, MD Dept. Otorhinolaryngology Khon Kaen Cancer Registry Faculty of Medicine Khon Kaen University THAILAND Staging is the attempt to assess the size
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationWho is the Ideal Candidate for PEG Intron?
Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationStaging for Residents, Nurses, and Multidisciplinary Health Care Team
Staging for Residents, Nurses, and Multidisciplinary Health Care Team Donna M. Gress, RHIT, CTR Validating science. Improving patient care. Learning Objectives Introduce the concept and history of stage
More informationNEW SURGICAL APPROACHES TO MELANOMA THERAPY
NEW SURGICAL APPROACHES TO MELANOMA THERAPY Melanoma 2003: New Insights Into Therapy & Treatment Douglas L. Fraker, M.D. University of Pennsylvania Surgical Treatment of Melanoma Primary resection margins
More informationExercise 15: CSv2 Data Item Coding Instructions ANSWERS
Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More information46. Merkel Cell Carcinoma
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationClinical Trial Results Database Page 1
Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationNo Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma
No Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma Michael Lowe, MD Assistant Professor of Surgery Winship Cancer Institute Emory University School of Medicine July
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Malignant Melanoma
Nth of Scotland Cancer Netwk Clinical Management Guideline f Malignant Melanoma Based on WOSCAN CMG with further consultation within NOSCAN UNCONTROLLED WHEN PRINTED Prepared by Approved by Issue date
More informationCancer Research Group Version Date: November 5, 2015 NCI Update Date: January 15, Schema. L O Step 1 1,2
Cancer esearch roup ev. 6/14, 2/15, 1/16 Step 2 Schema 5 Arm A: (7 weeks) Step 1 1,2 N Accrual: 515 S Arm S ransoral esection dissections S A N D M Z 4 ntermediate isk 7 Stratify: = 10 pk-yr vs. > 10 pk-yr
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More information47. Melanoma of the Skin
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationStudy Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus
Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationShould we still be performing IHC on all sentinel nodes?
Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationIndex. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035
Index Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, 947 948 Anorectal melanoma RT for, 1035 B Bacille Calmette-Guerin (BCG) in melanoma, 1008 BCG. See Bacille
More informationSubject Index. Dry desquamation, see Skin reactions, radiotherapy
Subject Index Actinic keratosis disseminated disease 42 surgical excision 42 AIDS, see Kaposi s sarcoma Amifostine, skin reaction prophylaxis 111 Basal cell carcinoma, superficial X-ray therapy Bowen s
More information5/8/2014. AJCC Stage Introduction and General Rules. Acknowledgements* Introduction. Melissa Pearson, CTR North Carolina Central Cancer Registry
AJCC Stage Introduction and General Rules Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
More information4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines
SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific
More informationCitation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n.
University of Groningen Primary and metastatic melanoma Francken, Anne Brecht IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More informationNodal Treatment in Melanoma: Snow to MSLT-II
Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,
More informationProposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationRadionuclide detection of sentinel lymph node
Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationRegistrar s Guide to Chapter 1, AJCC Seventh Edition. Overview. Learning Objectives. Describe intent and purpose of AJCC staging
Registrar s Guide to Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310 from The Centers for Disease Control
More informationWhat s New for 8 th Edition
What s New for 8 th Edition KCR 2018 SPRING TRAINING Overview What s New New Chapters for 8 th Editions Chapters That Split in 8 th Edition Merged 8 th Edition Chapters Blanks vs Xs How to Navigate Through
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationA PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL
A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationCancer of Unknown Primary (CUP)
Cancer of Unknown Primary (CUP) Pathways and Guidelines V1.0 London Cancer September 2013 The following pathways and guidelines document has been compiled by the London Cancer CUP technical subgroup and
More informationTable of contents. Page 2 of 40
Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationMEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES
MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES Although response is not the primary endpoint of this trial, subjects with measurable disease will be assessed by standard criteria. For the purposes of this
More informationWelcome to the RECIST 1.1 Quick Reference
Welcome to the RECIST 1.1 Quick Reference *Eisenhauer, E. A., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. Subject Eligibility
More informationMalignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationSentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma
Sentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma John A Zitelli MD Adjunct Clinical Associate Professor Dermatology, Otolaryngology, Plastic Surgery University of Pittsburgh
More informationMelanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationCollaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]
CS Tumor Size Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the physician's
More information6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationRationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York
Rationale For & Design of TAILORx Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Declining Breast Cancer Mortality & Event Rates in Adjuvant
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationDirectly Coded Summary Stage Melanoma
Directly Coded Summary Stage Melanoma National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control, National Program of Cancer Registries Directly Coded
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationMauricio Camus Appuhn Associate Professor Chief, Department of Surgical Oncology, Pontificia Universidad Católica de Chile
May 18-20, 2017 18 a 20 de Maio / 2017 Castro's Park Hotel Surgery for metastatic breast cancer: the controversy of local surgery for metastatic breast cancer Cirurgia em câncer de mama metastático: a
More informationSkin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice
Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationClinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma
ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationDescriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma
S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib
More informationWorld Articles of Ear, Nose and Throat Page 1
World Articles of Ear, Nose and Throat ---------------------Page 1 Primary Malignant Melanoma of the Tongue: A Case Report Authors: Nanayakkara PR*, Arudchelvam JD** Ariyaratne JC*, Mendis K*, Jayasekera
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationSynopsis. Study Phase and Title: Study Objectives: Overall Study Design
Synopsis Study Phase and Title: Study Objectives: Overall Study Design Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib
More informationManagement of the patient with Lymph Node Involvement. Michael A Henderson Peter MacCallum Cancer Center Univ of Melbourne
Management of the patient with Lymph Node Involvement Michael A Henderson Peter MacCallum Cancer Center Univ of Melbourne Lymph Node Field Recurrence Most important prognostic factor for early stage melanoma
More informationIntroduction & Descriptors
AJCC 8 th Edition Staging Introduction & Descriptors Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. The SHAPE Trial
Gynecologic Cancer InterGroup Cervix Cancer Research Network The SHAPE Trial Comparing radical hysterectomy and pelvic node dissection against simple hysterectomy and pelvic node dissection in patients
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationUpdates on management of the axilla in breast cancer the surgical point of view
Updates on management of the axilla in breast cancer the surgical point of view Edwige Bourstyn Centre des maladies du sein Hôpital Saint Louis Paris Sentinel lymph node biopsy (SLNB) is the standard of
More informationWork-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients
2018 AAD Annual Meeting, San Diego, CA Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion
More information6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms
6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant
More informationChapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationCON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer
CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University
More informationSurgical Oncology Perspective of Melanoma
Surgical Oncology Perspective of Melanoma Hans F. Schoellhammer, MD, FACS Assistant Clinical Professor Division of Surgical Oncology September 20, 2018 Nothing to disclose DISCLOSURE Discussion Objectives
More information